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Background.Systemiclupuserythematosus(SLE)isacompleximmunedisease.ThegeneticvariationintheIL-12bgenewasfound
to associate with SLE in Caucasian population. In this study, we examined this association in Chinese Han population by a recently
developed method, unlabeled probe-based high resolution melting analysis. Methods. A total of 297 SLE patients and 351 controls
were recruited. Unlabeled probe-based high resolution melting analysis (HRMA) was used in genotyping. Results.S t a t i s t i c a l l y
signiﬁcant diﬀerences were observed in both genotype and allele frequencies for rs6887695 in the SLE patients as compared with
the controls. Minor allele (C) of rs6887695 (P = 0.031, OR 0.78, [95% CI 0.63-0.98]) was found to be protective against SLE.
The association of SNP rs6887695 with the diagnostic criteria of SLE was also examined. Minor allele (C) exerts protective eﬀect
on the incidence of arthritis (P = 0.013, OR = 0.65, 95% CI = 0.47-0.92) and abnormalities of antinuclear antibody (P = 0.022,
OR = 0.68, 95% CI = 0.49–0.95). IL-12b SNPs were irrelevant to other diagnostic criteria of SLE. Summary. Polymorphisms of
rs6887695inIL-12bgenewereassociatedwithdiseaserisk,aswellasarthritisandantinuclearantibodysynthesis,ofsystemiclupus
erythematosus in Chinese population.
1.Introduction
Interleukin-12 (IL-12) is a heterodimeric cytokine that is
produced during innate immune response by monocytes,
macrophages, dendritic cells (DCs), neutrophils, and B cells
[1, 2]. The general function of IL-12 is thought to be as
an important immunomodulator linking innate recognition
of pathogens to development of adaptive immune response
[1, 3]. Interleukin (IL-12b), also known as p40, is one of
the components of IL-12 which covalently combine with
p35 (IL-12a) to form mature IL-12 protein. Otherwise, IL-
12b could also interact with p19 (IL-23a) to form the other
IL-12 family member, IL-23. IL-23 has strong capacity of
induction of a novel subset of T cells, the T-helper-17
(Th17) cells. These novel T-helper cells are characterized by
production of IL-17 cytokine which is strongly implicated
in the pathophysiology of various autoimmune diseases [4].
Owing to the important role of IL-12 and IL-23 during the
immune response, IL-12b, the common component of IL-
12 and IL-23, might be a candidate gene of autoimmune
disease. Indeed, IL-12b has been found to associate with sev-
eral autoimmune diseases including psoriasis, rheumatoid
arthritis, and type 1 diabetes [5–9].
Systemic lupus erythematosus (SLE) is a complex
autoimmune disease with multiple organs aﬀected. Autoan-
tibody production, formation of immune complexes and2 International Journal of Rheumatology
Table 1: Genotype and allele frequencies of IL-12b SNP rs6887695 in SLE cases and controls∗.













allele P OR (95% CI)
Genotype
or allele GG GC CC G C
Cases 297 107 (36.0) 153 (51.5) 37 (12.5) 0.019 367 (61.8) 227 (38.2) 0.031 0.78 (0.63–0.98)
Controls 351 114 (32.5) 164 (46.7) 73 (20.8) 392 (55.8) 310 (44.2)
∗SNP: single-nucleotide polymorphism; SLE: systemic lupus erythematosus; OR: odds ratios; 95% CI: 95% conﬁdence interval.
Table 2: Association of IL-12b SNP rs6887695 with clinical symptoms in SLE patients∗.













allele P OR (95% CI)
Genotype
or allele GG GC CC G C
Total cases 297 107 153 37 367 227
Rash
Positive 161 59 83 19 0.923 201 121 0.728 0.94 (0.68–1.31)
Negative 136 48 70 18 166 106
Photosensitivity
Positive 90 32 47 11 0.987 111 69 0.969 1.01 (0.70–1.44)
Negative 207 75 106 26 256 158
Arthritis
Positive 181 74 90 17 0.033 238 124 0.013 0.65 (0.47–0.92)
Negative 116 33 63 20 129 103
Oral ulcer
Positive 74 27 39 8 0.884 93 55 0.761 0.94 (0.64–1.38)
Negative 223 80 114 29 274 172























Figure 1: Derivative melting curves of unlabeled probes and
amplicon for genotyping of SNP rs6887695. Three genotypes (GG,
GC and CC) were discriminated as indicated in probe region.
tissue inﬂammation are the major clinical features of SLE.
The reported prevalence of SLE is 20 to 150 cases per 100,000
with a female/male ratio of 9:1 [10, 11]. The etiology of SLE
hasnotbeencompletelyunderstood,butitiswellknownthat
both genetic components and environmental factors con-
tribute to the pathogenesis of SLE [12, 13]. Recently, a series
of genome-wide association studies (GWAS) were employed
foridentifyingSLEassociatedgeneticvariants[14–19].These
studies provided new insights into the understanding of this
complex disease. In the Caucasian populations, it has been
suggested that a polymorphism rs6887695 located on IL-
12B gene was associated with SLE [19]. Here, we examined
this association in Chinese Han population by a recently
developed method, unlabeled probe-based high-resolution
melting analysis.
2. Methods
2.1. Patients. A total of 297 patients (27 males and 270
females; median age 29 years, range 12–55) who fulﬁlled the
American College of Rheumatology criteria for SLE [20]a n d
351 ethnically matched healthy controls (31 males and 320
females; median age 28 years, range 17–46) were recruited
from Shenzhen Hospital, Peking University. The control
group had neither family history nor symptoms related to
SLE. The study was approved by the institutional review
board of the Shenzhen Hospital, and written informed
consent was taken from all patients.International Journal of Rheumatology 3
Table 3: Association of IL-12b SNP rs6887695 with laboratory parameters in SLE patients∗.













allele P OR (95% CI)
Genotype
or allele GG GC CC G C
Total cases 297 107 153 37 367 227
Hematological
disorders
Positive 187 63 98 26 0.429 224 150 0.216 1.24 (0.88–1.76)
Negative 110 44 55 11 143 77
Proteinuria
≥0.5g/24h 101 35 52 14 0.851 122 80 0.617 1.09 (0.77–1.55)
<0.5g/24h 196 72 101 23 245 147
Antinuclear
antibody
≥1:320 168 67 87 14 0.032 221 115 0.022 0.68 (0.49–0.95)
<1:320 129 40 66 23 146 112
Anti-DNA
Positive 189 72 97 20 0.352 241 137 0.191 0.80 (0.57–1.12)
Negative 108 35 56 17 126 90
Anti-nRNP
Positive 81 31 41 9 0.846 103 59 0.581 0.90 (0.62–1.31)
Negative 216 76 112 28 264 168
Anti-Smith
Positive 68 24 37 7 0.783 85 51 0.845 0.96 (0.65–1.43)
Negative 229 83 116 30 282 176
Anti-Ro
(SSA)
Positive 118 43 61 14 0.968 147 89 0.837 0.97 (0.69–1.35)
Negative 179 64 92 23 220 138
Anti-La
(SSB)
Positive 72 25 38 9 0.963 88 56 0.848 1.04 (0.71–1.53)
Negative 225 82 115 28 279 171
C3 and C4
Decrease 133 49 79 15 0.399 177 109 0.960 0.99 (0.71–1.38)
Normal 164 58 74 22 190 118
∗SNP: single-nucleotide polymorphism; SLE: systemic lupus erythematosus; OR: odds ratios; 95% CI: 95% conﬁdence interval.
2.2. Genotyping. Genomic DNA was isolated from periph-
eral blood cells by using Innogent genomic DNA extraction
kit (Innogent, China) according to manufactory instruction.
Genotyping was assayed by high-resolution melting with
unlabeled probe as previously described [21]. Brieﬂy, asym-
metric PCR reaction was performed in a volume of 20µL
containing 20ng of genomic DNA, 1 × PCR buﬀer (Takara,
Japan),200µMdNTPs,0.5UrTaqDNApolymerase(Takara,
Japan), 0.05µMf o r w a r dp r i m e r ,0 . 5 µMe x c e s sr e v e r s e
primer, and 0.5µMC 3 - b l o c kp r o b e .T h eP C Rr e a c t i o n sw e r e
performed in an S1000 Thermal Cycler (Bio-Rad, USA);
the conditions included an initial denaturation at 94◦Cf o r
2min, followed by 45 cycles of 94◦C for 30s, 55◦Cf o r3 0s ,
and 72◦C for 20s and a ﬁnal extension at 72◦Cf o r5m i n u t e s .
The 10µL of PCR products was supplied with 1µLE v a G r e e n
(Bio-Rad, USA) and then subjected to HRM in CFX96 real-
time system C1000 Thermal Cycler (Bio-Rad, USA). The
samples were ﬁrst denatured at 95◦C for 30s and rapidly
cooled to 40◦Cf o r3 0sa n dt h e nm e l t e df r o m5 5 ◦Ct o9 0 ◦C
with a 0.3◦C/s ramp rate. Melting curves were analyzed with
Bio-Rad Precision Melt Analysis software (Bio-Rad, USA).
The sequences of the primers for rs6887695 were as follows:
forward 5 - GGT AAG TCA GTT TGA GAG AAG CA -3 ,
reverse 5 - CTA GGT CAC AAG CGT AGT AAA TG -3 ,a n d
unlabeled C3-blocked probe 5 - TGT AGT GTA GTG GTC
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Figure 2: Normalized melting curves and diﬀerence curves of unlabeled probe region for genotyping of SNP rs6887695. (a) The melting
curve was presented after normalization. Wild type GG genotype showed the lowest melting temperature since there was completely
mismatch between the unlabeled probe and wild type. (b) The diﬀerence curves were obtained by subtracting each curve from one
heterozygote (GC) curve. Three genotypes (GG, GC, and CC) were shown as indicated.
2.3. Statistical Analysis. The SNP was analyzed for an
association with the disease by means of comparison of
the minor allele frequency (MAF) in patients and controls
as well as the constancy of Hardy-Weinberg equilibrium
using chi square test or Fisher’s exact test. The magnitude
of association was expressed as odds ratio (OR) with a 95%




Probe. High-resolution melting analysis with unlabeled C3-
blocked probe was used for genotyping. As shown in
Figure 1, three genotypes (GG, GC, and CC) of SNP
rs6887695 (G > C) were accurately distinguished by the
derivative melting curves in the probe region. The derivative
melting curves directly from the PCR products were not
able to distinguish these genotypes (Figure 1, right part),
and the sensitivity and accuracy of HRMA were dramatically
improved using unlabeled probes (Figure 1,l e f tp a r t ) .A f t e r
furtheranalyzingonthenormalizedmeltingunlabeledprobe
region, we were able to discriminate all the genotypes clearly
(Figure 2(a)). The diﬀerence curves generated by subtracting
of one heterozygote curve displayed a much more clear
view for genotype discrimination (Figure 2(b)). Then, this
method was employed to screen our samples in the present
study.
3.2. Association of SNP rs6887695 with SLE. Table 1 shows
IL-12b rs6887695 genotype and allele frequencies in SLE
patients and healthy controls. Genotype frequencies were in
Hardy-Weinberg equilibrium in the patients and controls.
Statistically signiﬁcant diﬀerences were observed in both
genotype and allele frequencies for rs6887695 in the SLE
patients as compared with the controls. Minor alleles of
rs6887695 (P = 0.031, OR 0.78, [95% CI 0.63–0.98]) were
f o u n dt ob ep r o t e c t i v ea g a i n s tS L E .
3.3. Association of SNP rs6887695 with the Diagnostic Criteria
of SLE. In order to further analyze the possible signiﬁcance
of IL-12b SNPs in SLE, we compared the genotype and
allele frequencies of rs6887695 in diﬀerent diagnostic criteria
of SLE. Among the 11 criteria, serositis and neurological
disorders in our study were in low incidence and thus were
not subjected to statistical analysis.
Table 2 showed the analysis of IL-12b SNPs with the
clinical symptoms of SLE. We found that rs6887695 was
associated with the incidence of arthritis (P = 0.033), and
minor alleles (C) was protective against arthritis (P = 0.013,
OR = 0.65, 95% CI = 0.47–0.92). No obvious association was
observed between IL-12b SNPs and the incidence of other
clinical symptoms.
Table 3 showed the association of IL-12b SNPs with the
laboratory parameters of SLE. Interestingly, IL-12b SNPs
were associated with antinuclear antibody (P = 0.032).
Minor alleles (C) of rs6887695 were found to exert protective
eﬀect on the abnormalities of antinuclear antibody (P =
0.022, OR = 0.68, 95% CI = 0.49–0.95). IL-12b SNPs were
irrelevant to other laboratory parameters of SLE.
4. Discussion
Genotyping is an elementary method for SNP analysis.
High-resolution melting analysis (HRMA) is a cost-eﬀective
and high throughput method for SNP genotyping [22–
24]. However, it is sometimes diﬃcult to distinguish SNPs
of A/T or G/C (G/C in our case), which make up about
16% of human SNPs, because such SNPs cause only almost
undetectable Tm shift (less than 0.4◦C). Unlabeled probe
melting analysis is a modiﬁed HRMA in which a ∼30bp C3-
blocked probe is used to target the SNP of interest during
the melting. A single-base-pair diﬀerence in such a short
probe could result in a signiﬁcant Tm shift (e.g., 3-4◦C).
As shown in our study, we can discriminate almost all the
SNPsinamoreaccurateandreliablemannerusingunlabeled
probe melting analysis. Thus, the technology of HRMA
with unlabeled probe is strongly recommended for studying
genetic components of complex diseases such as SLE.
The association of IL-12b with several autoimmune
diseases has been well revealed [5–9]. SLE is a typical chronic
autoimmune disease caused by dysregulation of immuneInternational Journal of Rheumatology 5
system. As a common subunit of IL-12 and IL-23, IL-
12b could participate in regulation of several important
autoimmune responses especially in Th1 cell maturation
and Th17 cell development [1, 4]. However, there is little
evidence to suggest that IL-12b was associated with disease
risk of SLE up to now. In present study, we conﬁrmed that
SNP rs6887695 in the gene IL-12b was associated with SLE
in the Mainland Chinese Han population, which replicated
the ﬁndings from a GWAS study in Caucasian population
[19], while in a previous study, two SNPs located in the
promoter and 3 UTR region of IL-12b gene, respectively,
exhibited no association with the susceptibility of SLE in
Spanish population [25]. The discrepancy in these ﬁndings
may be explained by the fact that diﬀerent SNPs located
on IL-12b gene were examined in these studies. The SNP
rs6887695 was reported to be associated with psoriasis which
is also caused by dysregulation of autoimmune system [9].
Exploring the association of IL-12b with disease risk of SLE
in our and others’ work could provide us with a common
genetic background for autoimmune disease.
In this study, we also analyzed the association of SNP
rs6887695 with diﬀerent diagnostic criteria of SLE. The
potential role of rs6887695 in SLE was further proved by its
association with some of the clinical symptoms (arthritis)
and laboratory parameters (antinuclear antibody) of SLE.
The minor allele (C) of rs6887695 was found to be protec-
tive against such diagnostic criteria, indicating the aspects
through which rs6887695 exerts protective eﬀect on the risk
of SLE. This also implies that, at least in Chinese mainland
population, rs6887695 in IL-12b gene may not only be a
risk factor speciﬁc to SLE, but also might be a contributor
to the severity of this autoimmune disease. However, it is
not clear why rs6887695 has association with such particular
parameters. In the future, the underlying mechanism of
rs6887695 in SLE or other autoimmune diseases remains to
be more extensively studied.
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